Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
The Japanese health authorities have approved Cimzia (certolizumab pegol) to treat plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma for which existing treatment methods are not sufficiently effective. 28 January 2020
Biotechnology
In a Special Report, Patrick Laroche, Janssen EMEA Haematology Therapy Area Lead, looks at how haematology is leading the way in oncology innovation, how CAR-T has the potential to revolutionise treatment for multiple myeloma, and the challenges that lie ahead in this field. 28 January 2020
Biotechnology
Diabetes triplet medicine Trijardy (empagliflozin/linagliptin/metformin) has won approval from the US regulator as a therapy, along with diet and exercise, to lower blood sugar levels for adults with diabetes. 28 January 2020
Biotechnology
Swiss cancer giant Roche has submitted for approval in the USA to market Tecentriq (atezolizumab) plus Avastin (bevacizumab) for certain people with hepatocellular carcinoma (HCC). 27 January 2020
Biotechnology
German life sciences and pharma company Merck KGaA says it is investing 250 million euros ($276 million) in a new facility in Corsier-sur-Vevey, Switzerland – the Merck Biotech Development Center – dedicated to biotech development and manufacturing for clinical studies. 27 January 2020
Biotechnology
Venture capital firm Arix Bioscience has founded a new biotech, Quench Bio, aimed at developing candidates which inhibit the protein Gasdermin D, a target at the core of multiple inflammatory cell death pathways. 27 January 2020
Biotechnology
Japan Tobacco and Torii Pharmaceutical have received manufacturing and marketing approval for Corectim Ointment 0.5% (delgocitinib; formerly JTE-052), a Janus kinase (JAK) inhibitor, for an indication of atopic dermatitis in Japan. 27 January 2020
Biotechnology
In the search for non-opioid options to treat pain, Australian biotech Mesoblast has turned to a stem cell approach, which is currently in late-stage development for chronic low back pain. 25 January 2020
Biotechnology
As biotech companies making themselves eligible to a big pharma buyout go, Imugene appears to tick a lot of the boxes – but the proof of the pudding will come with all important trial results. 24 January 2020
Biotechnology
Blood products and vaccines specialist CSL Behring today announced that the Danish Medicines Council has published its final decision, approving human Alpha 1 Antitrypsin (AAT) therapy and Respreeza as standard treatment for slowing the progression of emphysema arising from Alpha 1 Antitrypsin Deficiency (AATD). 24 January 2020
Biotechnology
The Phase III IMvigor010 study evaluating Tecentriq (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of disease-free survival (DFS) compared to observation in people with muscle-invasive urothelial cancer (MIUC). 24 January 2020
Biotechnology
The US Food and Drug Administration on Thursday granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection (surgically removing all of a tissue, structure, or organ). 24 January 2020
Biotechnology
Detailed results from the Phase III SEQUOIA trial of pegilodecakin make for disappointing reading. 24 January 2020
Biotechnology
Late Thursday, French metabolic diseases biotech company Poxel announced the appointment of pharma industry veteran David Moller as chief scientific officer (CSO). 24 January 2020
Biotechnology
A negative decision from the National Institute for Health and Care Excellence (NICE) threatens the reimbursement potential for Stelara (ustekinumab) in the UK. 23 January 2020
Biotechnology
Japanese drugmaker Astellas Pharma has sold the stake in its joint venture (JV) with US biotech major Amgen. 23 January 2020
Biotechnology
Canadian biotech firm Zymeworks has announced the pricing of a public offering aimed at raising $279 million for the company. 23 January 2020
Biotechnology
UK clinical-stage biotech PureTech Health says it has sold 2.1 million shares of its affiliate Karuna Therapeutics for a cash consideration of around $200 million to Goldman Sachs & Co. 23 January 2020
Biotechnology
The Roivant Sciences company Dermavant has announced the appointment of Chris Chapman as its chief commercial officer. 22 January 2020
Biotechnology
A new report from industry analyst GlobalData finds that the compound annual growth rate (CAGR) of capital expenditure in public pharma companies increased by 4.7% between 2014 and 2018. 22 January 2020
All news
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze